MCL Literature Feed

A case report highlights chylothorax as a rare clinical presentation of mantle cell lymphoma, underscoring the need to consider malignancy in the differential diagnosis of this condition.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

Real-world data on the ibrutinib, lenalidomide, and rituximab triplet in relapsed/refractory non-Hodgkin lymphoma provides practical insights into the efficacy and safety of this chemotherapy-free regimen.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

This case report of sequential follicular lymphoma, MCL, and CML highlights the long-term risk of subsequent malignancies and severe infections (COVID-19-induced HLH) following repeated immunochemotherapy.

This case report of a rectal plasmacytoma misdiagnosed as MCL highlights a critical diagnostic pitfall, emphasizing the need for thorough pathological evaluation to prevent incorrect lymphoma-directed therapy.

This case report describes a rare, rapid progression from acute myopericarditis to pericardial calcification after initial CHOP chemotherapy, highlighting a severe, early-onset cardiotoxicity risk with this regimen.

New prognostic scores, AMOS and AMES, were developed for Indian MCL patients, showing better predictive accuracy than MIPI using simple clinical factors for improved risk stratification.

This first reported case of composite MCL and T-cell prolymphocytic leukemia highlights the diagnostic challenge of co-existing lymphoid malignancies, where an indolent T-PLL clone was present for years before diagnosis.

This MZL case identifies BTK C481S and PLCG2 D334H co-mutations driving zanubrutinib resistance, a mechanism highly relevant to BTKi failure and subsequent treatment strategies in relapsed MCL.

This study identifies predictors of outcome for covalent BTKi therapy in relapsed/refractory TP53-mutant MCL, helping to risk-stratify patients and guide subsequent treatment decisions.

The MCL35 gene expression assay identifies high-risk older patients who do not benefit from adding ibrutinib to bendamustine-rituximab, mandating alternative frontline strategies for this molecularly-defined subgroup.

This review outlines strategies like non-viral vectors, allogeneic products, and point-of-care manufacturing to reduce CAR-T therapy costs, potentially increasing access for relapsed/refractory MCL patients.

M2-like macrophages secrete IL-1 receptor antagonist (IL-1ra), impairing CAR-T19 function in MCL, suggesting targeting the IL-1 pathway could overcome this novel resistance mechanism.

The novel metabolism-targeting agent KAT/3BP demonstrates preclinical activity in aggressive B-cell lymphomas, introducing a new therapeutic class with potential future applications for treating MCL.

This phase 1 study shows the novel chemo-free triplet of magrolimab (anti-CD47), obinutuzumab, and venetoclax is a potential strategy for relapsed/refractory B-cell lymphomas, including MCL.

The combination of ibrutinib and venetoclax improves progression-free survival in relapsed/refractory MCL, establishing a highly effective, chemotherapy-free regimen for this difficult-to-treat population.

This preclinical study demonstrates potent anti-MCL activity with a triple combination of bendamustine, acalabrutinib, and venetoclax, providing a strong rationale for future clinical trials.

A targeted NGS panel characterized the mutational landscape of Korean lymphomas, including MCL, demonstrating its utility for identifying clinically relevant mutations like TP53 in diverse subtypes.

This case report documents the rare clinical presentation of mantle cell lymphoma as multiple rectal lesions, highlighting an unusual pattern of gastrointestinal involvement for clinicians to consider.

This conference report identifies key controversies in B-cell lymphoma management, initiating a formal process to develop expert consensus guidelines for navigating increasingly complex treatment selection and sequencing decisions.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

In Chinese patients with relapsed/refractory MCL previously treated with a covalent BTKi, the non-covalent BTKi pirtobrutinib achieved a 62.9% overall response rate, confirming its global efficacy.

A rare composite MCL/LPL case reveals a cryptic IGK::CCND1 fusion driving the MCL, highlighting the diagnostic utility of molecular testing for atypical CCND1 rearrangements.

The Japanese Society of Hematology's 2023 guidelines provide updated, evidence-based recommendations on risk stratification and treatment algorithms for managing mantle cell lymphoma in clinical practice.

This case report describes therapy-related acute megakaryoblastic leukemia after autologous transplant for MCL, highlighting a rare but severe long-term toxicity of intensive consolidation therapy.

This review outlines the evolving MCL treatment paradigm, emphasizing earlier BTKi use, established CAR-T, and emerging non-covalent BTKi and bispecifics for high-risk disease like TP53-mutated MCL.

This review contrasts European and American perspectives on integrating autologous transplant, CAR-T, and allogeneic transplant into MCL treatment, offering clinical guidance in a rapidly evolving therapeutic landscape.

An updated indirect comparison suggests zanubrutinib provides significantly longer progression-free survival than orelabrutinib in relapsed/refractory MCL, informing BTKi choice in the absence of head-to-head trial data.